Nicholas Mills

#BHF Professor of Cardiology @EdinUniCVS | Data Driven Innovation Lead @EdinUniUsher | Associate Ed @CircAHA | #NHS Interventional Cardiologist #troponin

[Nicholas Mills @HighSTEACS]

PROPOSAL for a new clinical classification of acute myocardial infarction

Published online today @NatureMedicine
Open access link: https://t.co/Z8uaTd2Lty
#ESC2023 🧵[1/10]

[Peder L. Myhre MD, PhD @pmyhre]

The wonderful @CircAHA team presenting highlights from recent publications in the journal…
and the Social Media work 😁 #ESCCongress2024

We now have ~75 000 followers on X and #CirculationOnTheRun podcast has > 1 mill downloads and 75000 🙌🏻

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

Announcing our @TheLancet commission on inequalities & disparities in cardiovascular health led by @RBugiardini , cochaired by me & @cpgale3 with our amazing WG @MaasAngela @DrSoniaAnand1 @PoojaJha2015 @OliviaManfrini et al
@SmidtHeart @CedarsSinaiMed

📎https://t.co/JKbNGJzagt

[UCSD Biomarker Symposium @BiomarkerSymp]

Don't forget to register for the 18th Annual Biomarkers Symposium! Abstract submission deadline EXTENDED to Monday, April 29- submit your abstracts and case reports, and see you on Friday, May 3! https://t.co/G40IlEQ0Db
@UCSDHealth @UCSDCardiology @ucsdim

[Nicholas Mills @HighSTEACS]

@DrMarkRoss Thanks for sharing this. Interesting study. The absolute differences were very small though (<1 ng/L) and not clear how loss to follow up might have impacted this endpoint, but encouraging none the less

[Takeshi Fujisawa @BiomkrT]

The @HighSTEACS lab is recruiting! looking for an enthusiastic & talented individual to join our #biomarker lab https://t.co/5OcAvTGUdW
@EdinUniCVS

Job advert: https://t.co/uQxHiNEMKu Closing date 1st April 2024 #jobs #laboratory #technician #biomedicalscientist
Please Share!

[ATVB: An AHA Journal @atvbahajournals]

Additive antithrombotic effects of PAR4 antagonism in patients with coronary artery disease receiving single or dual antiplatelet therapies @HighSTEACS @SamuelDebono @jennynashville
https://t.co/HvkYZFAOV6

[Alex Warren @alexfwarren]

Really excited to share the results of the EPOCHS study, a collaborative multicentre observational study of cardiogenic shock in Scotland.

Highlights:
➡️ CS = 3% of ICU admissions in 🏴󠁧󠁢󠁳󠁣󠁴󠁿
➡️ Half due to acute MI, half other causes
➡️ 30-day mortality 54%

https://t.co/VPfD4MDKXP

[Nicholas Mills @HighSTEACS]

@J_Boeddinghaus @RIE_Lothian @RIECathLab @UniSpitalBasel @CRIBasel @chapdoc1 @RongBing5 @HenriksenDr @andabularga @CaelanTaggart @RyanWereski @MartinDenvir @TzolosEvangelos @KuanKenLee @UniSpitalBasel have a superb interventional cardiologist, researcher and colleague coming! Thank you for joining us in Edinburgh and for your brilliant contribution ⭐️

[Nicholas Mills @HighSTEACS]

@cpgale3 Primary outcome modified during conduct as event rate for MACE so low. This was due to exclusion of MI patients with diabetes, heart failure and renal disease where drug already indicated.

[Nicholas Mills @HighSTEACS]

#Scotland the best place to train in Cardiology again

[BJCA 📊 @TheBJCA]

🚨🚨Based on @TheBJCA annual survey data, we have released the 2023 Annual Region Reports for UK Cardiology training 🚨🚨

➡️ https://t.co/lNB7jsrMkT

Where does your deanery rank?

⬇️⬇️⬇️

[Dr Claire E Hastie @DrClaireEHastie]

Latest @NatureComms paper from Long-Covid In Scotland Study. Following adjustment for potential confounders, the attributable prevalence of ongoing symptoms at 6, 12, and 18 months post-infection is 6.6%, 6.5%, and 10.4% respectively #LongCovid #COVID19
https://t.co/Y4icXrNcNw

[The BMJ @bmj_latest]

A high sensitivity cardiac troponin I assay in the assessment of patients with suspected acute coronary syndrome was associated with a reduced risk of subsequent myocardial infarction or death in those reclassified by the assay, finds study https://t.co/Gt4H8Pk8Zm

[Ken Lee @KuanKenLee]

Perhaps detecting all those non-ACS troponin elevations is benefitting our patients after all...?

5-year outcomes of the HighSTEACS trial published today in @bmj_latest

https://t.co/dYxbmpMgOO

@HighSTEACS @DDoudesis
@BHFScotland @dataloch

1/n

[Nicholas Mills @HighSTEACS]

@jdrwilcox Josh, I think you are right. Need to work out how to help this group of patients

[Nicholas Mills @HighSTEACS]

@DrToddLee All cause mortality was an absolute 10% lower at 5 years in patients reclassified by high- sensitivity troponin. Not sure this matter to an immortal time lord though? @DrToddLee

[Nicholas Mills @HighSTEACS]

Implementation of a high sensitivity cardiac troponin I assay and risk of myocardial infarction or death at five years: observational analysis of a stepped wedge, cluster randomised controlled trial https://t.co/bETs5X5MaT

[Nicholas Mills @HighSTEACS]

@cpgale3 @bmj_latest Indeed in those without other high risk symptoms or signs an abnormal blood test is more likely to change the patient's course. We need evidence-based care pathways here.

[Nicholas Mills @HighSTEACS]

@DavidLBrownMD David I am an international cardiologist in the NHS in Scotland. I treat patients based on the evidence available and their preference. There is a role for PCI in stable angina, but for many medical therapy is sufficient. There is no less-is-more, there is just good care.

[Nicholas Mills @HighSTEACS]

@DavidLBrownMD Not a quantum leap, but a well conducted double-blind, sham controlled trial that demonstrates PCI is effective. Where is the bias?

[Yader Sandoval @yadersandoval]

Enjoyed sharing and discussing at #AHA23 emerging opportunities addressing machine learning for the prediction of acute MI: there are multiple avenues worth exploring with biomarkers, ECG, and imaging but we’ll need well curated data, validation, and RCTs.